TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Theralase Technologies ( (TSE:TLT) ) has issued an announcement.
Theralase Technologies announced the publication of independent preclinical data showcasing the effectiveness of its antiviral candidate, Ruvidar®, in combating Herpes Simplex Virus Type 1 (HSV-1). The study highlights Ruvidar®’s superior performance compared to Acyclovir® and Metformin®, offering significant inhibitory effects on the virus without the need for light activation. This positions Ruvidar® as a promising next-generation antiviral therapy, particularly for drug-resistant HSV-1 infections, and supports its advancement into clinical development.
The most recent analyst rating on (TSE:TLT) stock is a Buy with a C$0.70 price target. To see the full list of analyst forecasts on Theralase Technologies stock, see the TSE:TLT Stock Forecast page.
Spark’s Take on TSE:TLT Stock
According to Spark, TipRanks’ AI Analyst, TSE:TLT is a Neutral.
Theralase Technologies’ overall stock score is primarily influenced by its weak financial performance and bearish technical indicators. While the company has promising clinical developments and strategic plans, these are overshadowed by ongoing financial struggles and negative market momentum.
To see Spark’s full report on TSE:TLT stock, click here.
More about Theralase Technologies
Theralase Technologies Inc. is a clinical stage pharmaceutical company that specializes in developing light, radiation, sound, and drug-activated therapeutics for treating cancer, bacteria, and viruses.
Average Trading Volume: 83,120
Technical Sentiment Signal: Sell
Current Market Cap: C$47.56M
Learn more about TLT stock on TipRanks’ Stock Analysis page.